68ga-nota-exendin-4
PeptideexperimentalImaging agent
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02560376)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Glucagon-like peptide 1 receptorRadiopharmaceutical
GLP1R radiopharmaceutical
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 68-Gallium
Oral
No
Parenteral
No
Topical
No
Also known as
- 68ga-nota-exendin-4
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05034783 | Early Phase 1 (Phase 1) | Oct 1, 2021 | Chinese Academy of Medical Sciences |
| NCT04979611 | Phase 1 | Aug 1, 2020 | Fujian Medical University |
| NCT04185350 | Early Phase 1 (Phase 1) | May 5, 2019 | Nanjing Medical University |
| NCT02560376 | Early Phase 1 (Phase 1) | Feb 1, 2014 | National Institutes of Health (NIH), Tsinghua University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2014 |
| Tsinghua University | Academic/Hospital | 1 | 1 | 1 | 2014 |
5 organizations
Page 1 / 1